Navigation Links
InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
Date:1/5/2012

BRISBANE, Calif., Jan. 5, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited net sales of Esbriet® (pirfenidone) for the fourth quarter ended December 31, 2011, as well as information on the number of patients that initiated Esbriet therapy in Germany during 2011.  InterMune also highlighted its recent business and clinical development activities, including new efficacy data from the RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF), and provided forward-looking operating expense guidance for 2012. 

Esbriet Launch in Germany 

InterMune estimates that approximately 612 patients have been prescribed Esbriet in Germany since the mid-September launch.  Of these 612 patients, approximately 172 patients were enrolled in the Named Patient Program (NPP) in Germany and were transitioned to commercial supply during the recently completed quarter.  The balance, or approximately 440 patients were prescribed Esbriet as new patients during the quarter. 

A total of 410 patients were enrolled in the NPP outside of Germany as of December 31, 2011, bringing the total number of new patient starts on Esbriet therapy across Europe to approximately 1,022 during 2011.

InterMune today reported that unaudited net sales of Esbriet in Germany during the fourth quarter of 2011 totaled approximately $2.7 million.  Unaudited net sales of Esbriet totaled approximately $2.8 million since its launch in mid-September 2011.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "We are extremely pleased that the German launch of Esbriet, the first commercial launch in Europe, continues to meet our high expectations both qualitatively and quantitatively.  These early results affirm our view that Esbriet has the potenti
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Appoints Angus C. Russell to Board of Directors
2. InterMune to Release Third Quarter Financial Results on November 3
3. InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
4. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
5. InterMune Receives European Union Approval for Esbriet® (pirfenidone)
6. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
7. InterMune to Present at J.P. Morgan Healthcare Conference
8. InterMune Reports Third Quarter 2010 Financial Results
9. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
10. InterMune to Release Second Quarter Financial Results on July 27
11. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  World Hemp Oil, an importer of ... they are now offering legal, organic oil with high ... strains grown in medical marijuana states. People suffering from ... as Parkinson,s, MS, and spinal cord injury, no longer ... because imported CBD Oil Is legal in all states. ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
(Date:11/21/2014)... BRYDGES, Ontario , Nov. 20, 2014 /PRNewswire/ ... monitor mounting solutions and reading room environment guidance, ... their newest musculoskeletal radiology reading room, which may ... room designs at Penn Medicine. ... by the American College of Radiology,s Imaging 3.0 ...
Breaking Medicine Technology:New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 2RedRick Technologies Helps Penn Radiology Implement New Radiology Reading Room Concepts 3
... Jan. 2 Amicus Therapeutics,Inc. (Nasdaq: FOLD ), ... Officer, will present a corporate update at the 26th ... January 7,2008 at 11:30 am (Pacific Standard Time) at ... be webcast live and may be accessed by visiting,Amicus, ...
... Inc. (Nasdaq: ALTH ) today announced that ... pre-specified 65-patient,safety review of data from the Company,s ... patients with relapsed or refractory peripheral,T-cell lymphoma (PTCL), ... the,protocol. This interim assessment was based upon an ...
Cached Medicine Technology:Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 2Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 2Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 3Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 4Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma 5
(Date:11/23/2014)... To show thanks to new and old ... white evening dresses for weddings. Customers who need ... iFitDress.com is a distinguished dress manufacturer, and it is among ... customers for a very long time. The CEO of this ... will be able to buy not only a beautiful dress, ...
(Date:11/23/2014)... Washington, DC (PRWEB) November 23, 2014 ... monthly Tech Report , which features the latest ... a technology expert and reporter for NewsWatch, conducted the ... cameras are unique and powerful options in the car ... is rising and it can be hard to find ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, ... attire in order to prepare for the wedding season. ... 70% off. , UWDress.com is a reliable company that ... especially the new items -- formal wedding guest attire. This ... market, including superstar and princess. As one of the leading ...
(Date:11/22/2014)... 22, 2014 Setria® Glutathione is ... approved it for use “as a therapeutically active ... within the Therapeutic Goods (Listing) Notice 2014 (No. ... Hakko’s Setria® Glutathione will be exclusivity distributed in ... sources and imports fine chemicals to Australian manufacturers. ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3
... to Attend Conference, LAS VEGAS, Sept. 10 ... http://www.skinvisible.com ), the developers,of Invisicare(R), a proprietary ... announced that Mr. Terry Howlett,President & CEO, will ... & Co.,Investor Summit on September 18, 2007 at ...
... Montague and Wolf Haldenstein Obtain Third-Largest Settlement,in Securities ... PHILADELPHIA, Sept. 10 Judge Morris E.,Lasker ... of Massachusetts has,granted final approval of a $52.5 ... actions against Sepracor Inc., a,Massachusetts-based pharmaceutical company (Nasdaq: ...
... a protein best known as a common marker of inflammation ... The research, published by Cell Press in the September issue ... a potential target for cancer treatment. , CRP is a ... during the process of inflammation in response to the inflammatory ...
... eating fattening foods and not getting enough exercise are all ... disease more so if you have a family history. ... women dont change these habits as often as men, even ... reporting in the September issue of the American Heart ...
... Expansion of Services Now Ranges From Birth Through ... The Exceptional,Children,s Foundation (ECF) announced today that it ... one of California,s largest and most,unique nonprofit organizations ... disabilities. As a result of the,merger, ECF becomes ...
... Abbott (NYSE:,ABT) -- the global health care company ... Index and the Dow Jones Sustainability North America,Index ... Abbott,s,continued leadership in business, environmental and social performance. ... approach to business," said,Miles D. White, chairman and ...
Cached Medicine News:Health News:Skinvisible to Present at Merriman Curhan Ford & Co.'s Investor Summit 2007 2Health News:$52.5 Million Settlement Against Sepracor Inc. Approved 2Health News:Human C-reactive protein regulates myeloma tumor cell growth and survival 2Health News:Women less likely than men to change habits that increase heart disease risk 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 2Health News:Exceptional Children's Foundation Merger with Kayne Eras Center Creates One of State's Most Comprehensive Nonprofits Serving the Disabled 3Health News:Dow Jones Sustainability Index Again Recognizes Abbott for Continued Leadership in Business, Environmental and Social Performance 2
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Clear Advantage® is a premium 100% latex-free, self-adhering, one-piece catheter designed for maximum wear. It features aloe in the adhesive, and a kink-resistant nozzle designed to eliminate blo...
... all-silicone non-adhesive male external catheter is ... latex-related allergic reactions. It is designed ... change external catheters several times a ... catheter comes with an adjustable strap ...
Medicine Products: